Can't speak about PRR Ramses, but with NEN, I mean, essentially there you were dealing with a severe lack of transparency vis a vis an unknown quantity, and I don't think that applies to PBT. There are already hard results out re: efficacy, it's just about how good, and whether it's enough to get FDA (and, given the dearth of effective treatments, it should be). Seems PBT2 should at the very least be a mild success, where NEN was always at the mercy of the unknown quantity being the tenements.
You only live once - this is a gamble I'd regret not taking!
cowan conference, page-28
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $38.48K | 12.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 77190096 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 6269051 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |